DocMorris Aktie

DocMorris für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A0Q6J0 / ISIN: CH0042615283

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
15.07.2025 07:00:04

gematik extends DocMorris CardLink approval until January 2027

DocMorris AG / Key word(s): Miscellaneous
gematik extends DocMorris CardLink approval until January 2027

15.07.2025 / 07:00 CET/CEST


Frauenfeld, 15 July 2025

Press release

gematik extends DocMorris CardLink approval until January 2027

  • Approval extension ensures seamless transition to successor technology PoPP
  • gematik will also enable contactless use of the eGK without a PIN in the context of PoPP

gematik has extended the product approval for DocMorris' CardLink solution until the end of January 2027. Patients can therefore continue to redeem their e-prescriptions with their electronic health card (eGK) and the DocMorris app, while at the same time a seamless transition to the successor technology PoPP (Proof of Patient Presence) is ensured.

“We welcome the fact that gematik worked with all parties involved at an early stage to find a transitional arrangement for fully digital e-prescription redemption until the nationwide introduction of PoPP. By enabling the contactless use of the eGK without a PIN, even in the context of PoPP, our customers can continue to rely on learned redemption methods for their e-prescriptions in the future,” says Walter Hess, CEO DocMorris.

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

19 August 2025 2025 Half-year results (conference call/webcast)
16 October 2025 Q3/2025 Trading update
20 January 2026 Sales 2025
19 March 2026 2025 Full-year results and outlook 2026 (conference call/webcast)
16 April 2026 Q1/2026 Trading update
12 May 2026 Annual General Meeting, Zurich
19 August 2026 2026 Half-year results (conference call/webcast)
15 October 2026 Q3/2026 Trading update

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 



End of Media Release


Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 2169628

 
End of News EQS News Service

2169628  15.07.2025 CET/CEST

Analysen zu DocMorris AG (ex Zur Rose)mehr Analysen

10:15 DocMorris Hold Deutsche Bank AG
11.07.25 DocMorris Buy Jefferies & Company Inc.
03.07.25 DocMorris Hold Deutsche Bank AG
04.06.25 DocMorris Buy Jefferies & Company Inc.
03.06.25 DocMorris Add Baader Bank
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

DocMorris AG (ex Zur Rose) 8,19 2,50% DocMorris AG (ex Zur Rose)